for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aileron Therapeutics Inc

ALRN.OQ

Latest Trade

1.45USD

Change

-0.08(-5.23%)

Volume

151,590

Today's Range

1.42

 - 

1.53

52 Week Range

0.25

 - 

1.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.53
Open
1.48
Volume
151,590
3M AVG Volume
27.91
Today's High
1.53
Today's Low
1.42
52 Week High
1.98
52 Week Low
0.25
Shares Out (MIL)
38.18
Market Cap (MIL)
58.41
Forward P/E
-2.23
Dividend (Yield %)
--

Latest Developments

More

Aileron Therapeutics Reports Qtrly Loss Per Share $0.14

Aileron Therapeutics Announces Pricing Of Public Offering Of Common Stock

Aileron Reports Positive Interim Results From Trial Of ALRN-6924

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aileron Therapeutics Inc

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Industry

Biotechnology & Drugs

Contact Info

490 Arsenal Way

WATERTOWN, MA

02472-2870

United States

+1.617.9950900

http://www.aileronrx.com/

Executive Leadership

Jeffrey A. Bailey

Chairman of the Board

Manuel C. Aivado

President, Chief Executive Officer, Director

Rick Wanstall

Chief Financial Officer, Treasurer

D. Allen Annis

Senior Vice President - Research

Vojislav Vukovic

Senior Vice President, Chief Medical Officer

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-3.040

2018

-2.140

2019

-1.200

2020(E)

-0.656
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-180.62
Return on Equity (TTM)
-135.15

Latest News

Latest News

BRIEF-Aileron Therapeutics - Received A Letter Notifying Co It Had Regained Compliance With Nasdaq's Minimum Bid Price Requirement

* AILERON THERAPEUTICS - RECEIVED A LETTER NOTIFYING CO IT HAD REGAINED COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: https://bit.ly/3hjQ8y8 Further company coverage:

BRIEF-Aileron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* AILERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Aileron Reports Positive Interim Results From Trial Of ALRN-6924

* AILERON THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1B/2 CLINICAL TRIAL OF ALRN-6924 FOR THE PREVENTION OF TOPOTECAN-INDUCED TOXICITIES DURING TREATMENT FOR SMALL CELL LUNG CANCER

BRIEF-Aileron Therapeutics Reports First Quarter 2020 Financial Results And Provides Corporate Update

* AILERON THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Aileron Therapeutics Announces Plans To Release Interim Results From Its Phase 1B/2 Myelopreservation Study In Mid-2020

* AILERON THERAPEUTICS ANNOUNCES PLANS TO RELEASE INTERIM RESULTS FROM ITS PHASE 1B/2 MYELOPRESERVATION STUDY IN MID-2020

BRIEF-Aileron Therapeutics Reports Qtrly Loss Per Share Of $0.26

* AILERON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Aileron Therapeutics Names John Longenecker As Interim CEO

* AILERON THERAPEUTICS INC - JOHN P. LONGENECKER HAS BEEN NAMED INTERIM CHIEF EXECUTIVE OFFICER

BRIEF-Aileron Therapeutics Q1 Loss Per Share $0.52

* AILERON THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Aileron Therapeutics Reports Q4 Loss Of $0.47 Per Share

* AILERON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aileron Therapeutics Appoints Jeffrey Bailey As Chairman Of Board

* AILERON THERAPEUTICS APPOINTS JEFFREY A. BAILEY TO ITS BOARD OF DIRECTORS

BRIEF-Apple Tree Partners Sells 150,000 Shares Of Aileron Therapeutics Inc's Common Stock On Jan 9

* APPLE TREE PARTNERS II LP REPORTS SALE OF 150,000 SHARES OF AILERON THERAPEUTICS INC'S COMMON STOCK ON JAN 9 AT $9.80 PER SHARE - SEC FILING Source text: (http://bit.ly/2DiFGmF) Further company coverage:

BRIEF-Aileron Therapeutics posts Q3 loss of $0.45 per share

* Aileron therapeutics reports third quarter 2017 financial results

BRIEF-Aileron Therapeutics reports second quarter 2017 financial results

* Aileron Therapeutics reports second quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up